Fidaxomicin denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for fidaxomicin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Fidaxomicin for "Prior Authorization Required"

UnitedHealthcare requires prior authorization (PA) for fidaxomicin on most of its commercial and Medicare Advantage plans. Because CDI is an acute infection that may require prompt treatment, a PA denial — whether for failure to obtain authorization in advance, an incomplete submission, or a retroactive denial after the drug was dispensed in an urgent setting — can create significant access barriers. Understanding the PA criteria and the appeal pathway is essential to resolving the denial quickly.

## Why This Denial Is Appealable

PA denials are among the most frequently overturned denial types when the clinical documentation is complete. UHC's PA criteria for fidaxomicin are defined in its published medical or pharmacy policy, and the prescriber has the right to demonstrate that those criteria are met. If the drug was dispensed before PA was obtained because the clinical situation was urgent, that urgency is a recognized basis for a retroactive authorization request and for expedited appeal.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or ACA §2719 within the deadline on your Explanation of Benefits. Request the PA criteria UHC applied.
• External review: After an adverse internal decision, request IRO review within approximately four months.
• Expedited review: CDI is an acute condition. If fidaxomicin is urgently needed or already dispensed due to urgent clinical need, request expedited internal appeal (72-hour decision) and concurrent expedited external review, with a physician statement of medical urgency.
• Retroactive PA: If the drug was dispensed without PA due to urgency, explicitly request retroactive authorization review and document the clinical circumstances that precluded advance PA submission.

## Documentation to Gather

• Lab-confirmed diagnosis: PCR, toxin, GDH, or culture results confirming C. difficile infection.
• Episode and severity characterization: Physician notes documenting the episode type (initial, recurrent) and clinical severity, matching the categories in UHC's PA criteria.
• Prior treatment history with dates and outcomes: Documentation of prior CDI treatment courses — agent, duration, and response — particularly if prior treatment failure or recurrence is part of UHC's PA criteria for fidaxomicin.
• Urgency documentation (if retroactive): Prescriber statement explaining why fidaxomicin was dispensed before PA was obtained, including the clinical timeline and the risk of delay.
• Prescriber medical-necessity letter: A letter from the treating physician addressing each of UHC's PA criteria, referencing IDSA/SHEA guideline organization recommendations generically, and explaining why fidaxomicin is the appropriate agent for this patient.
• UHC's PA criteria for fidaxomicin: Obtain the current published PA requirements from UHC's provider portal or coverage policy. Identify every criterion and confirm which ones UHC claims are unmet.

## Criteria-Mapping Structure

| UHC Prior-Authorization Criterion | Source | How Your Case Satisfies It | |---|---|---| | [Verbatim PA criterion from UHC policy] | [Policy name/section] | [Specific chart fact, lab date, note reference] |

Ensure the prescriber's letter addresses each criterion individually. The most common reason PA appeals fail is that the physician letter speaks generally to medical necessity without mapping to the insurer's specific checklist. A criterion-by-criterion response dramatically improves success rates.